Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioSeek has entered into a deal to use its BioMap systems to characterize compounds identified by GlaxoSmithKline. Financial terms of the agreement were not disclosed.
Subscribe to our email newsletter
BioMap profiling can provide in-depth characterization of drug function, including defining mechanism of action and secondary activities, and can provide insights into potential clinical applications.
BioMap systems are designed to replicate the intricate cell and pathway interactions present in human disease biology. Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMap profiles) that can be compared to a large number of reference profiles in BioSeek’s database.
“We are excited to be working closely with the innovative scientific teams in GSK as we continue to demonstrate the utility of BioMap Systems to drive drug discovery,” commented Peter Staple, CEO of BioSeek. “This collaboration will enable us to make use of the full range of applications of our technology.”